Grail (NASDAQ:GRAL) Trading Down 7.4% – Should You Sell?

Grail, Inc. (NASDAQ:GRAL) fell 7.4% during mid-day trading on Tuesday . The company traded as low as $18.14 and last traded at $18.21. 127,209 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 383,007 shares. The stock had previously closed at $19.67.

Analysts Set New Price Targets

GRAL has been the topic of a number of research reports. Morgan Stanley assumed coverage on shares of Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price on the stock. Wolfe Research started coverage on Grail in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Guggenheim began coverage on Grail in a research report on Thursday, October 17th. They set a “neutral” rating for the company.

Grail Price Performance

The business’s fifty day moving average is $17.80.

Insider Activity

In other news, CFO Aaron Freidin sold 30,452 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now owns 268,277 shares of the company’s stock, valued at $3,761,243.54. This trade represents a 10.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at $8,589,507.22. The trade was a 16.77 % decrease in their position. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Grail

An institutional investor recently bought a new position in Grail stock. Douglas Lane & Associates LLC bought a new stake in Grail, Inc. (NASDAQ:GRAL) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 169,977 shares of the company’s stock, valued at approximately $3,034,000. Douglas Lane & Associates LLC owned 0.51% of Grail at the end of the most recent reporting period.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.